Collegium Pharmaceutical Q4 Earnings Call Highlights [Yahoo! Finance]
Collegium Pharmaceutical, Inc. (COLL)
Last collegium pharmaceutical, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.collegiumpharma.com
Company Research
Source: Yahoo! Finance
Collegium Pharmaceutical (NASDAQ:COLL) reported record financial results for the fourth quarter and full year 2025, driven by continued growth in its ADHD product Jornay PM and steady performance across its pain portfolio. Management highlighted progress on three strategic priorities: expanding Jornay PM, maximizing durability of the pain franchise, and deploying capital to enhance shareholder value. Record 2025 results and cash generation Chief Executive Officer Vikram Karnani said 2025 marked “transformative growth” for the company, with strong commercial execution and strategic capital deployment. Collegium grew full-year net revenues by 24% and adjusted EBITDA by 15%, achieving its annual financial guidance. The company also generated more than $329 million in cash from operations and ended 2025 with over $386 million in cash, up roughly $224 million from the end of 2024. Karnani noted the company's net leverage ratio ended the year at less than 1x adjusted EBITDA, a target i
Show less
Read more
Impact Snapshot
Event Time:
COLL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COLL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COLL alerts
High impacting Collegium Pharmaceutical, Inc. news events
Weekly update
A roundup of the hottest topics
COLL
News
- Collegium Pharmaceutical (COLL) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "buy (b-)" to "hold (c+)".MarketBeat
- Collegium to Present New Real-World Data at PainConnect 2026GlobeNewswire
- Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community [Yahoo! Finance]Yahoo! Finance
- Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD CommunityGlobeNewswire
- Collegium to Participate in Upcoming Investor ConferencesGlobeNewswire
COLL
Earnings
- 2/26/26 - Beat
COLL
Sec Filings
- 3/5/26 - Form 4
- 3/3/26 - Form 144
- 2/26/26 - Form 10-K
- COLL's page on the SEC website